Search results for Ontamalimab

Ontamalimab Biosimilar – Anti-MADCAM1 mAb – Research Grade, ProteoGenix, PX-TA1498

Description of Ontamalimab Biosimilar - Anti-MADCAM1 mAb - Research Grade Introduction Ontamalimab Biosimilar is a novel monoclonal antibody (mAb) that targets the protein MADCAM1. This protein is involved in the inflammatory response and has been identified as a therapeutic target for various autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Ontamalimab Biosimilar as a research-grade antibody. Structure of Ontamalimab Biosimilar Ontamalimab Biosimilar is a humanized IgG1 monoclonal antibody, meaning it is derived from human antibody sequences but has been modified to have a longer half-life and lower immunogenicity. It is composed of two heavy chains and two light chains, each with a variable region that binds specifically to MADCAM1. The constant region of the antibody is responsible for its effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Ontamalimab Biosimilar Ontamalimab Biosimilar specifically targets MADCAM1, a cell adhesion molecule that is expressed on the surface of endothelial cells in the gut. MADCAM1 plays a crucial role in the recruitment of immune cells to sites of inflammation, making it an attractive therapeutic target for autoimmune diseases such as Crohn’s disease and ulcerative colitis. By binding to MADCAM1, Ontamalimab Biosimilar blocks the interaction between this protein and its receptor, α4β7 integrin, thereby preventing the migration of immune cells to the gut and reducing inflammation. Applications of Ontamalimab Biosimilar Ontamalimab Biosimilar is currently being evaluated in clinical trials for the treatment of inflammatory bowel disease (IBD), specifically Crohn’s disease and ulcerative colitis. These are chronic autoimmune diseases that affect the digestive tract and can cause symptoms such as abdominal pain, diarrhea, and rectal bleeding. Current treatments for IBD include immunosuppressants and biologic therapies, but they are not effective for all patients and can have significant side effects. Ontamalimab Biosimilar offers a promising alternative as a targeted therapy for IBD. In addition to IBD, Ontamalimab Biosimilar may also have potential applications in other autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. These diseases also involve inflammation and immune cell recruitment, making MADCAM1 a relevant therapeutic target. Further research and clinical trials are needed to explore the efficacy of Ontamalimab Biosimilar in these indications. Conclusion In summary, Ontamalimab Biosimilar is a research-grade antibody that specifically targets MADCAM1, a protein involved in the inflammatory response. Its structure as a humanized IgG1 antibody and its activity in blocking the interaction between MADCAM1 and its receptor make it a promising therapeutic option for autoimmune diseases such as IBD. Further research and clinical trials will help determine the full potential of Ontamalimab Biosimilar in treating various autoimmune diseases.

Ontamalimab, Abbexa, abx831457

Ontamalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MADCAM1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ontamalimab (SHP 647) is a fully human IgG2 monoclonal antibody targeting mucosal localization protein cell adhesion molecule (MADCAM1).

Ontamalimab ELISA Kit, ProteoGenix, KPTX248

Description of Ontamalimab ELISA Kit Introduction Ontamalimab, also known as Santolimab, is a human monoclonal antibody that targets the inflammatory cytokine interleukin-23 (IL-23). It is currently being developed as a potential therapy for autoimmune diseases such as Crohn’s disease and ulcerative colitis. In order to accurately measure the levels of ontamalimab in patient samples, an enzyme-linked immunosorbent assay (ELISA) kit has been developed. This article will provide a scientific description of the Ontamalimab ELISA Kit, including its structure, activity, and application. Structure of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit consists of a 96-well microplate coated with a specific anti-ontamalimab antibody. This antibody is immobilized on the surface of the microplate and serves as the capture antibody. The kit also includes a biotinylated detection antibody, which binds to ontamalimab in the sample. This detection antibody is then detected by a streptavidin-HRP conjugate, which produces a colorimetric signal in the presence of a substrate. The intensity of this signal is directly proportional to the amount of ontamalimab present in the sample. Activity of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit is a highly sensitive and specific method for quantifying the levels of ontamalimab in patient samples. The kit has a detection limit of 1 ng/mL and a dynamic range of 2-100 ng/mL. This allows for accurate measurement of ontamalimab levels in both low and high concentration samples. The kit also has a high inter- and intra-assay precision, with coefficients of variation of less than 10%. Application of Ontamalimab ELISA Kit The Ontamalimab ELISA Kit has a wide range of applications in both research and clinical settings. In research, the kit can be used to measure the pharmacokinetics of ontamalimab, as well as to monitor the levels of ontamalimab in preclinical and clinical studies. In clinical settings, the kit can be used to monitor the response to ontamalimab therapy in patients with autoimmune diseases. By measuring the levels of ontamalimab in patient samples, clinicians can assess the effectiveness of the therapy and make necessary adjustments to the treatment plan. Conclusion In conclusion, the Ontamalimab ELISA Kit is a valuable tool for accurately measuring the levels of ontamalimab in patient samples. Its high sensitivity, specificity, and precision make it a reliable method for monitoring ontamalimab therapy in patients with autoimmune diseases. As ontamalimab continues to be developed as a potential therapeutic option for various autoimmune diseases, the Ontamalimab ELISA Kit will play a crucial role in its clinical and research applications.

Ontamalimab ELISA Kit, Abbexa, abx395137

Ontamalimab ELISA Kit is a quantitative ELISA kit for detection of Ontamalimab.Ontamalimab (SHP647) is a fully human, immunoglobulin G2 , antihuman mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody being developed for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). A population pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted using clinical phase 2 study data to evaluate the PK and PD of ontamalimab following subcutaneous administrations of 7.5, 22.5, 75, and 225 mg every 4 weeks in patients with moderate to severe UC or CD. A total of 440 patients with UC (n = 249; 56.6%) or CD (n = 191; 43.4%) were included in the analysis. A 2-compartment model with parallel linear and nonlinear elimination adequately characterized concentration-time profiles of ontamalimab. The apparent clearance and volume of distribution were 0.0127 L/h (0.305 L/day) and 6.53 L, respectively. Apparent clearance and volume of distribution were mainly dependent on baseline albumin and body weight, respectively. No differences in the PK properties of ontamalimab were observed between patients with UC or CD. The presence of antidrug antibodies did not impact the PK of ontamalimab. Nonlinear elimination occurred at very low concentrations and was unlikely to contribute to the elimination half-life under steady-state conditions. A linear PK/PD model described the relationship between ontamalimab and free MAdCAM-1. Minimum concentrations of ontamalimab at steady state following 75 mg every 4 weeks were associated with >95% suppression of circulating free MAdCAM-1. The PK/PD properties characterized support phase 3 testing in UC and CD.

Research Grade Ontamalimab (HC589016), abinScience, HC589016

Ontamalimab Biosimilar - Research Grade, ichor.bio, ICH5734